Scott T Schepers1, David L Arndt1, Robert D Rogers2, Donald Hedeker3, Harriet de Wit4. 1. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S Maryland Ave, MC3077, Chicago, IL, 60637, USA. 2. School of Psychology, Bangor University, Gwynedd, Wales, UK. 3. Department of Public Health Sciences, University of Chicago, Chicago, IL, USA. 4. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S Maryland Ave, MC3077, Chicago, IL, 60637, USA. hdew@uchicago.edu.
Abstract
RATIONALE: One risk factor for alcohol and substance misuse is hypomanic experiences, or periods of mood elevation. Young people who report hypomanic states are more likely to develop bipolar disorder (BP), and BP and other mood disorders increase the risk of addiction. We recently reported that young adults with a history of mood elevation experience less subjective effects from a low dose of alcohol, which may be predictive of future alcohol use. The finding with alcohol raised the question of whether this dampened response to a drug also applies to other drugs, such as amphetamine. OBJECTIVE: This study assessed responses of d-amphetamine in healthy young adults with varying experiences of mood elevation, as measured by the Mood Disorders Questionnaire (MDQ). METHODS: Healthy 18-19-year-olds (N = 30) with a range of MDQ scores participated in three 4-h laboratory sessions in which they received placebo, 10 mg, or 20 mg d-amphetamine. They completed mood questionnaires and cardiovascular measures. RESULTS: Individuals with higher MDQ scores reported less stimulation and euphoria after 10 mg, but not 20 mg, d-amphetamine, than individuals with lower scores. MDQ scores were not related to cardiovascular responses to the drug. CONCLUSIONS: A history of mood elevation experiences or hypomania states is related to dampened response to a low dose of a psychostimulant drug, extending previous findings with dampened response to alcohol. This phenotype for mood disorders of dampened responses to drugs may contribute to risk for subsequent drug use or misuse.
RATIONALE: One risk factor for alcohol and substance misuse is hypomanic experiences, or periods of mood elevation. Young people who report hypomanic states are more likely to develop bipolar disorder (BP), and BP and other mood disorders increase the risk of addiction. We recently reported that young adults with a history of mood elevation experience less subjective effects from a low dose of alcohol, which may be predictive of future alcohol use. The finding with alcohol raised the question of whether this dampened response to a drug also applies to other drugs, such as amphetamine. OBJECTIVE: This study assessed responses of d-amphetamine in healthy young adults with varying experiences of mood elevation, as measured by the Mood Disorders Questionnaire (MDQ). METHODS: Healthy 18-19-year-olds (N = 30) with a range of MDQ scores participated in three 4-h laboratory sessions in which they received placebo, 10 mg, or 20 mg d-amphetamine. They completed mood questionnaires and cardiovascular measures. RESULTS: Individuals with higher MDQ scores reported less stimulation and euphoria after 10 mg, but not 20 mg, d-amphetamine, than individuals with lower scores. MDQ scores were not related to cardiovascular responses to the drug. CONCLUSIONS: A history of mood elevation experiences or hypomania states is related to dampened response to a low dose of a psychostimulant drug, extending previous findings with dampened response to alcohol. This phenotype for mood disorders of dampened responses to drugs may contribute to risk for subsequent drug use or misuse.
Authors: Lisa H Berghorst; Poornima Kumar; Doug N Greve; Thilo Deckersbach; Dost Ongur; Sunny J Dutra; Diego A Pizzagalli Journal: Bipolar Disord Date: 2016-11-10 Impact factor: 6.744
Authors: Joseph R Calabrese; Robert M A Hirschfeld; Michael Reed; Marilyn A Davies; Mark A Frye; Paul E Keck; Lydia Lewis; Susan L McElroy; James P McNulty; Karen D Wagner Journal: J Clin Psychiatry Date: 2003-04 Impact factor: 4.384
Authors: Anne Halmøy; Helene Halleland; Margaretha Dramsdahl; Per Bergsholm; Ole Bernt Fasmer; Jan Haavik Journal: J Clin Psychiatry Date: 2010-01 Impact factor: 4.384
Authors: Anissa Abi-Dargham; Lawrence S Kegeles; Diana Martinez; Robert B Innis; Marc Laruelle Journal: Eur Neuropsychopharmacol Date: 2003-12 Impact factor: 4.600
Authors: Xavier Caseras; Natalia S Lawrence; Kevin Murphy; Richard G Wise; Mary L Phillips Journal: Am J Psychiatry Date: 2013-05 Impact factor: 18.112
Authors: Neil B Varshneya; Kelly E Dunn; Caitlyn J Grubb; Sandra I Okobi; Andrew S Huhn; Cecilia L Bergeria Journal: Exp Clin Psychopharmacol Date: 2022-03-10 Impact factor: 3.492
Authors: Sunjeev K Kamboj; Hannah Zhao; Luzia Troebinger; Giulia Piazza; Emma Cawley; Vanessa Hennessy; Georges Iskandar; Ravi K Das Journal: Int J Neuropsychopharmacol Date: 2021-07-23 Impact factor: 5.176